Division of Pfizer Inc.
Latest From Redvax GmbH
Emerging Company Profile: Austria's privately-held Hookipa Biotech just raised $60m to progress two proof of concept clinical trials for its lead development programs. It will eventually seek a public listing.
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
Pfizer sees long-term growth potential in vaccines, fueled by new products targeted to patients across their life, from unborn children to seniors, including a portfolio of vaccines targeted to pregnant women and therapeutic cancer vaccines.
The company envisions maternal immunization as a new prong in its strategy to protect a full spectrum of people from disease through vaccinations, ranging from unborn children to senior citizens.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
- Christian Schaub, Managing Dir.
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.